Clinical Reviews:

Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis

Zhengqiang Bao _, Chao Cao, Xinwei Geng, Baoping Tian, Yanping Wu, Chao Zhang, Zhihua Chen, Wen Li, Huahao Shen and Songmin Ying

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:7629-7639. https://doi.org/10.18632/oncotarget.5367

Metrics: PDF 1667 views  |   HTML 2313 views  |   ?  


Zhengqiang Bao1,2,*, Chao Cao1,*, Xinwei Geng2, Baoping Tian1, Yanping Wu1, Chao Zhang1, Zhihua Chen1, Wen Li1, Huahao Shen1,3, Songmin Ying1,2

1Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Institute of Respiratory Diseases, Zhejiang University School of Medicine, Hangzhou, China

2Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, China

3State Key Laboratory for Respiratory Diseases, Guangzhou, China

*These authors have contributed equally to this work

Correspondence to:

Songmin Ying, e-mail: [email protected]

Huahao Shen, e-mail: [email protected]

Keywords: clinical trials, PARP, BRCA, cancer, synthetic lethality, Olaparib

Received: June 22, 2015     Accepted: August 28, 2015     Published: September 22, 2015


Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of small-molecule drugs suppressing PARP enzymes activity, inducing the death of cells deficient in homologous recombination repair (HRR). HRR deficiency is common in tumor cells with BRCA gene mutation. Since their first clinical trial in 2003, PARP inhibitors have shown benefit in the treatment of HRR-deficient tumors. Recently, several randomized clinical trials (RCTs) have been conducted to investigate the potential benefit of administration of PARP inhibitors in cancer patients. However, the results remain controversial. To evaluate the efficiency and safety of PARP inhibitors in patients with cancer, we performed a comprehensive meta-analysis of RCTs. According to our study, PARP inhibitors could clearly improve progression-free survival (PFS), especially in patients with BRCA mutation. However, our study showed no significant difference in overall survival (OS) between the PARP inhibitors and controls, even in the BRCA mutation group. Little toxicity was reported in the rate of treatment correlated adverse events (AEs) in PARP inhibitor group compared with controls. In conclusion, PARP inhibitors do well in improving PFS with little toxicity, especially in patients with BRCA deficiency.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5367